The Aspirin-maker can’t shake off recent mistakes | DW Business

It’s one of Europe’s major industrial players, but Bayer continues to struggle. It’s takeover of controversial seed- and chemicals-giant Monsanto in 2018 saddled it with billions in legal fees and payments from the pesticide known as “Roundup.” New court judgments added to its woes this year – Bayer stock is down 30 percent from the beginning of 2023. Investors are growing restless.

Chapters:

0:00 Background on Bayer
1:22 Rolf Fricker, Oliver Wyman Strategy Advisors

Subscribe: https://www.youtube.com/user/deutschewelleenglish?sub_confirmation=1

For more news go to: http://www.dw.com/en/
Follow DW on social media:
►Facebook: https://www.facebook.com/deutschewellenews/
►Twitter: https://twitter.com/dwnews
►Instagram: https://www.instagram.com/dwnews
►Twitch: https://www.twitch.tv/dwnews_hangout
Für Videos in deutscher Sprache besuchen Sie: https://www.youtube.com/dwdeutsch
#bayer #aspirin #monsanto

Source